Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Terminated 3Completed 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Renal Cell 6Kidney Neoplasms 4Melanoma 1

Interventions

aldesleukin 43Sunitinib 42Cyclophosphamide 30Nivolumab 29pembrolizumab 27Everolimus 27Interferon-alpha 25Bevacizumab 23Sorafenib 22Interleukin-2 20fludarabine phosphate 19Radiotherapy 18Ipilimumab 18Filgrastim 18Axitinib 18Gene Expression Profiling 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14Radiosurgery 13fludarabine 11Doxorubicin 11Carboplatin 11Blood Specimen Collection 11temsirolimus 10atezolizumab 9Immunohistochemistry 9Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Kidney Neoplasms × peginterferon alfa-2b × Genitourinary × Clear all
NCT00090870 2018-07-12

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

Medical University of South Carolina

Phase 2 Terminated
10 enrolled 4 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00467077 2017-03-17

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

California Cancer Consortium

Phase 2 Terminated
21 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00589550 2015-06-08

PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Terminated
1 enrolled 2 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00045279 2013-06-05

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡